Frontiers | Novel Vaccine Technologies in Veterinary Medicine: A Herald to Human Medicine Vaccines
Gold-Nanostar-Chitosan-Mediated Delivery of SARS-CoV-2 DNA Vaccine for Respiratory Mucosal Immunization: Development and Proof-of-Principle | ACS Nano
EFFICACY OF BIOBOS IBR MARKER VACCINE
Vaccines | Free Full-Text | A Universal Influenza Virus Vaccine Candidate Tested in a Pig Vaccination-Infection Model in the Presence of Maternal Antibodies
Vaccine principle established by Pasteur. P. multocida virulence is... | Download Scientific Diagram
Complement Factors in COVID-19 Therapeutics and Vaccines: Trends in Immunology
Accepted Manuscript
Figure 10 from Third generation DIVA vaccine towards classical swine fever virus. Efficacy in face of maternal immunity | Semantic Scholar
The effect of an mRNA vaccine against COVID-19 on endothelial function and arterial stiffness | Hypertension Research
Marker Vaccine - an overview | ScienceDirect Topics
DIVA metabolomics: Differentiating vaccination status following viral challenge using metabolomic profiles | PLOS ONE
![PDF] A Novel E2 Glycoprotein Subunit Marker Vaccine Produced in Plant Is Able to Prevent Classical Swine Fever Virus Vertical Transmission after Double Vaccination | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/fd9d65047c6bec38de5545071b19e13fb19de6d1/5-Table1-1.png "PDF] A Novel E2 Glycoprotein Subunit Marker Vaccine Produced in Plant Is Able to Prevent Classical Swine Fever Virus Vertical Transmission after Double Vaccination | Semantic Scholar")
PDF] A Novel E2 Glycoprotein Subunit Marker Vaccine Produced in Plant Is Able to Prevent Classical Swine Fever Virus Vertical Transmission after Double Vaccination | Semantic Scholar
FAQ: DIVA vaccines and diagnostics - Epizone
Semisynthetic Glycoconjugate Vaccine Candidates against Escherichia coli O25B Induce Functional IgG Antibodies in Mice | JACS Au
Immunogenicity of chimeric haemagglutinin-based, universal influenza virus vaccine candidates: interim results of a randomised, placebo-controlled, phase 1 clinical trial - The Lancet Infectious Diseases
Vaccines | Free Full-Text | Methods for Measuring T-Cell Memory to Vaccination: From Mouse to Man
Bacteria-enabled oral delivery of a replicon-based mRNA vaccine candidate protects against ancestral and delta variant SARS-CoV-2: Molecular Therapy
Carbohydrates and Immunology: Synthetic Oligosaccharide Antigens for Vaccine Formulation - Morelli - 2011 - European Journal of Organic Chemistry - Wiley Online Library
Advances in COVID-19 mRNA vaccine development | Signal Transduction and Targeted Therapy
Viruses | Free Full-Text | Comparative Study of Optical Markers to Assess Bait System Efficiency Concerning Vaccine Release in the Oral Cavity of Dogs
Biobos IBR Marker Vaccine
Intranasal vaccination with a lentiviral vector protects against SARS-CoV-2 in preclinical animal models - ScienceDirect
1. The marker vaccine principle (after Franken, 2009a,b). | Download Scientific Diagram
Can a Vaccine for Covid-19 Be Developed in Record Time? - The New York Times
DIVA (Differentiating Infected from Vaccinated Animals) vaccines and strategies
Frontiers | Emerging Concepts and Technologies in Vaccine Development
Delivery routes for better T cell outcomes
Frontiers | Beyond Just Peptide Antigens: The Complex World of Peptide-Based Cancer Vaccines
